Testing effectiveness (Phase 2)Study completedNCT03728634
What this trial is testing
Evaluate the Safety and Tolerability, as Well as the Pharmacokinetic and Pharmacodynamic Profiles of Single and Multiple Doses of Eplontersen Administered Subcutaneously to Healthy Volunteers and Patients With Hereditary Transthyretin-Mediated Amyloidosis (hATTR ).
Who this might be right for
Healthy VolunteershATTR Amyloidosis
Ionis Pharmaceuticals, Inc. 47